PRINCETON, N.J., Oct. 8 NJ-Pharmasset-conf
PRINCETON, N.J., Oct. 8 /PRNewswire-FirstCall/ -- Pharmasset, Inc.
(Nasdaq: VRUS) management will present at the Natixis Bleichroeder Hidden Gems
Conference being held from October 13-14, 2008 at the Waldorf Astoria in New
York City. Michelle Berrey, Pharmasset's Chief Medical Officer, will provide
an overview of the company on Monday, October 13, 2008, at 11:30 AM (ET).
About Pharmasset
Pharmasset is a clinical-stage pharmaceutical company committed to
discovering, developing and commercializing novel drugs to treat viral
infections. Pharmasset's primary focus is on the development of oral
therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus
(HCV) and human immunodeficiency virus (HIV).
Pharmasset is currently developing three product candidates. Clevudine,
for the treatment of chronic HBV infection, is enrolling Phase 3 clinical
trials for registration in North, Central and South America and Europe.
Clevudine is already approved for HBV in South Korea and marketed by Bukwang
Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral
treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in
combination with Pegasys(R) plus Copegus(R) through a strategic collaboration
with Roche. Racivir, which is being developed for the treatment of HIV in
combination with other approved HIV drugs, has completed a Phase 2 clinical
trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.
Contact
Richard E.T. Smith
Vice President of Investor Relations
richard.smith@pharmasset.com
Office: +1 (609) 613-4181
SOURCE Pharmasset, Inc.
